TY - JOUR
T1 - The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project
T2 - Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors
AU - IASLC Staging and Prognostic Factors Committee and of the Advisory Boards
AU - Ruffini, Enrico
AU - Rami-Porta, Ramon
AU - Huang, James
AU - Ahmad, Usman
AU - Appel, Sarit
AU - Bille, Andrea
AU - Boubia, Souheil
AU - Brambilla, Cecilia
AU - Cangir, Ayten Kayi
AU - Cilento, Vanessa
AU - Detterbeck, Frank
AU - Falkson, Conrad
AU - Fang, Wentao
AU - Filosso, Pier Luigi
AU - Giaccone, Giuseppe
AU - Girard, Nicolas
AU - Guerrera, Francesco
AU - Infante, Maurizio
AU - Kim, Dong Kwan
AU - Lucchi, Marco
AU - Marino, Mirella
AU - Marom, Edith M.
AU - Nicholson, Andrew G.
AU - Okumura, Meinoshin
AU - Rimner, Andreas
AU - Simone, Charles B.
AU - Asamura, Hisao
AU - Rusch, Valerie
AU - Araujo, Luiz Henrique
AU - Beer, David
AU - Bertoglio, Pietro
AU - Beyruti, Ricardo
AU - Brambilla, Elisabeth
AU - Cangir, A. K.
AU - Connolly, Casey
AU - Darling, Gail
AU - Dibaba, Daniel
AU - D’ Journo, Xavier Benoit
AU - Eberhardt, Wilfried
AU - Erasmus, Jeremy
AU - Fennell, Dean
AU - Fong, Kwun
AU - Galateau-Salle, Françoise
AU - Gill, Ritu R.
AU - Giroux, Dorothy
AU - Giuliani, Meredith
AU - Goo, Jin Mo
AU - Hirsch, Fred
AU - Hoffman, Hans
AU - Kernstine, Kemp
N1 - Funding Information:
Disclosures: Dr. Asamura reports receiving grants and personal fees from Johnson and Johnson and Covidien Japan; grants from Taiho, Astellas, AstraZeneca, and Eli Lilly, outside of the submitted work. Dr. Boubia reports receiving personal fees from Medtronic and AstraZeneca, outside of the submitted work. Dr. Marom reports receiving other support from Boehringer Ingelheim and Merck Sharp & Dohme, outside of the submitted work. Dr. Nicholson reports receiving grants and personal fees from Pfizer; personal fees from Merck, Boehringer Ingelheim, Novartis, AstraZeneca, Bristol-Myers Squibb, Roche, AbbVie, Oncologica, UpToDate, European Society of Oncology, and Liberum, outside of the submitted work. Dr. Rimner reports receiving grants and personal fees from Boehringer Ingelheim, AstraZeneca, and Merck; grants from Pfizer and Varian Medical Systems; nonfinancial support from Philips/Elekta; and personal fees from Cybrexa, MoreHealth, and ResearchToPractice outside of the submitted work. The remaining authors declare no conflict of interest.
Funding Information:
Disclosures: Dr. Asamura reports receiving grants and personal fees from Johnson and Johnson and Covidien Japan; grants from Taiho, Astellas, AstraZeneca , and Eli Lilly, outside of the submitted work. Dr. Boubia reports receiving personal fees from Medtronic and AstraZeneca , outside of the submitted work. Dr. Marom reports receiving other support from Boehringer Ingelheim and Merck Sharp & Dohme , outside of the submitted work. Dr. Nicholson reports receiving grants and personal fees from Pfizer ; personal fees from Merck , Boehringer Ingelheim, Novartis , AstraZeneca , Bristol-Myers Squibb , Roche , AbbVie, Oncologica, UpToDate, European Society of Oncology, and Liberum, outside of the submitted work. Dr. Rimner reports receiving grants and personal fees from Boehringer Ingelheim, AstraZeneca, and Merck; grants from Pfizer and Varian Medical Systems; nonfinancial support from Philips/Elekta; and personal fees from Cybrexa, MoreHealth, and ResearchToPractice outside of the submitted work. The remaining authors declare no conflict of interest.
Publisher Copyright:
© 2022 International Association for the Study of Lung Cancer
PY - 2022
Y1 - 2022
N2 - Thymic epithelial tumors are presently staged using a consistent TNM classification developed by the International Association for the Study of Lung Cancer (IASLC) and approved by the Union for International Cancer Control and the American Joint Committee on Cancer. The stage classification is incorporated in the eight edition of the TNM classification of thoracic malignancies. The IASLC Staging and Prognostic Factors Committee (SPFC)—Thymic Domain (TD) is in charge for the next (ninth) edition expected in 2024. The present article represents the midterm report of the SPFC-TD: in particular, it describes the unresolved issues identified by the group in the current stage classification which are worth being addressed and discussed for the ninth edition of the TNM classification on the basis of the available data collected in the central thymic database which will be managed and analyzed by Cancer Research And Biostatistics. These issues are grouped into issues of general importance and those specifically related to T, N, and M categories. Each issue is described in reference to the most recent reports on the subject, and the priority assigned by the IASLC SPFC-TD for the discussion of the ninth edition is provided.
AB - Thymic epithelial tumors are presently staged using a consistent TNM classification developed by the International Association for the Study of Lung Cancer (IASLC) and approved by the Union for International Cancer Control and the American Joint Committee on Cancer. The stage classification is incorporated in the eight edition of the TNM classification of thoracic malignancies. The IASLC Staging and Prognostic Factors Committee (SPFC)—Thymic Domain (TD) is in charge for the next (ninth) edition expected in 2024. The present article represents the midterm report of the SPFC-TD: in particular, it describes the unresolved issues identified by the group in the current stage classification which are worth being addressed and discussed for the ninth edition of the TNM classification on the basis of the available data collected in the central thymic database which will be managed and analyzed by Cancer Research And Biostatistics. These issues are grouped into issues of general importance and those specifically related to T, N, and M categories. Each issue is described in reference to the most recent reports on the subject, and the priority assigned by the IASLC SPFC-TD for the discussion of the ninth edition is provided.
KW - IASLC
KW - Staging
KW - Thymic tumors
KW - TNM
UR - http://www.scopus.com/inward/record.url?scp=85129395065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129395065&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2022.03.005
DO - 10.1016/j.jtho.2022.03.005
M3 - Article
C2 - 35321838
AN - SCOPUS:85129395065
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
ER -